A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design.
The objectives of this retrospective analysis were (1) to characterize the population pharmacokinetics (popPK) of four different monoclonal antibodies (mAbs) in a combined analysis of individual data collected during first-in-human (FIH) studies and (2) to provide a scientific rationale for prospective design of FIH studies with mAbs. The data set was composed of 171 subjects contributing a total of 2716 mAb serum concentrations, following intravenous (IV) and subcutaneous (SC) doses. mAb PK was described by an open 2-compartment model with first-order elimination from the central compartment and a depot compartment with first-order absorption. Parameter values obtained from the popPK model were further used to generate optimal sampling times for a single dose study. A robust fit to the combined data from four mAbs was obtained using the 2-compartment model. Population parameter estimates for systemic clearance and central volume of distribution were 0.20 L/day and 3.6 L with intersubject variability of 31% and 34%, respectively. The random residual error was 14%. Differences (> 2-fold) in PK parameters were not apparent across mAbs. Rich designs (22 samples/subject), minimal designs for popPK (5 samples/subject), and optimal designs for non-compartmental analysis (NCA) and popPK (10 samples/subject) were examined by stochastic simulation and estimation. Single-dose PK studies for linear mAbs executed using the optimal designs are expected to yield high-quality model estimates, and accurate capture of NCA estimations. This model-based meta-analysis has determined typical popPK values for four mAbs with linear elimination and enabled prospective optimization of FIH study designs, potentially improving the efficiency of FIH studies for this class of therapeutics.
1Amgen Inc. Pharmacokinetics and Drug Metabolism; Seattle, WA, South San Francisco, CA, and Thousand Oaks, CA USA.
Jasmine P
JP
Davda
1Amgen Inc. Pharmacokinetics and Drug Metabolism; Seattle, WA, South San Francisco, CA, and Thousand Oaks, CA USA.
Michael G
MG
Dodds
1Amgen Inc. Pharmacokinetics and Drug Metabolism; Seattle, WA, South San Francisco, CA, and Thousand Oaks, CA USA.
Megan A
MA
Gibbs
1Amgen Inc. Pharmacokinetics and Drug Metabolism; Seattle, WA, South San Francisco, CA, and Thousand Oaks, CA USA.
Wendy
W
Wisdom
1Amgen Inc. Pharmacokinetics and Drug Metabolism; Seattle, WA, South San Francisco, CA, and Thousand Oaks, CA USA.
John
J
Gibbs
D061605:Administration, Intravenous; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D008954:Models, Biological; D013269:Stochastic Processes
D000911:Antibodies, Monoclonal
drug development; first in human; meta-analysis; monoclonal antibody; optimal design; population pharmacokinetics